The emergence of Next-Generation Sequencing (NGS) has revolutionized the way of reaching a genome sequence, with the promise of potentially providing a comprehensive characterization of DNA variations. Nevertheless, detecting somatic mutations is still a difficult problem, in particular when trying to identify low abundance mutations such as subclonal mutations, tumour-derived alterations in body fluids or somatic mutations from histological normal tissue. The main challenge is to precisely distinguish between sequencing artefacts and true mutations, particularly when the latter are so rare they reach similar abundance levels as artefacts. Here, we present needlestack, a highly sensitive variant caller, which directly learns from the data the level of systematic sequencing errors to accurately call mutations. Needlestack is based on the idea that the sequencing error rate can be dynamically estimated from analyzing multiple samples together. We show that the sequencing error rate varies across alterations, illustrating the need to precisely estimate it. We evaluate the performance of needlestack for various types of variations, and we show that needlestack is robust among positions and outperforms existing state-of-the-art method for low abundance mutations.
INTRODUCTION
Massive parallel sequencing, or next generation sequencing (NGS), has revolutionized the manner in which genetic variation can be explored, due to a large increase in throughput and unprecedented ability to detect low-abundance variations compared to the traditional Sanger sequencing, and at a greatly reduced cost per sequenced base. However, because these new technologies are prone to errors, identifying genetic variants from NGS data remains a considerable challenge (1) . This is particularly true in heterogeneous samples, where the variant allelic fractions (VAF, the ratio of the number of sequencing reads carrying the mutant allele to the total read count) deviate away from the expectations of a diploid genome (0%, 50% or 100% for the three possible diploid genotypes), until the point where the mutant alleles make up only a small fraction of the sequenced reads, approaching the background error rate. Nevertheless, robustly identifying low VAF sequence variants in such heterogeneous settings can be highly informative, for example providing insights into the clonal evolution of tumours (2) , analyzing the cell-free DNA in order to identify tumour-derived molecular footprints (3), or evaluating somatic mutations in histologically normal material (4) .
The error rate of next generation sequencing is known to vary across DNA base pairs and even across multiple base changes at the same DNA position (5, 6) . NGS errors originate from many of the steps in the sequencing process, stemming from the quality of the template DNA, its subsequent fragmentation, the library preparation, the base calling, or the alignment step subsequent to the sequencing of raw reads. Some of these errors have a tendency to reoccur consistently across samples whereas others have a more unpredictable appearance. The net effect of NGS being made of errors from multiple sources is that they become highly difficult to distinguish or correct (7) . Variant identification methods that consider this highly variable error pattern may improve our ability to robustly detect true sequence variants even when their abundance is low. Most current algorithms use a probabilistic model on VAF applied independently across samples to distinguish between sequencing artifacts and true variations (8) , while methods specifically designed to detect low abundance mutation, like shearwaterML (9, 10) , propose to benefit from the shared knowledge on errors across samples, but are limited by the requirement of a prior threshold on the error rate.
Here, we have explored the approach of using multiple samples analyzed concurrently to develop an error model for each potential base change. Sequence variants are identified as outliers relative to this robust error model. This method, called needlestack, allows the identification of sequencing variants in a dynamic manner relative to the variable error pattern found in NGS data, and is particularly appropriate to call variants that are rare in the sequenced material. By combining this method with additional laboratory processing for further error correction (11) and very deep next generation sequencing, we are able to robustly identify VAFs well below 1% while maintaining acceptable false discovery rates. We conducted multiple rigorous performance estimations and comparisons with methods for both somatic and germline variant detection. We deployed our pipeline focusing on efficiency and robustness using the Domain-Specific Language (DSL) nextflow (12) , and on reproducibility by providing Docker and Singularity images. Source code is versioned and freely available on GitHub (https://github.com/IARCbioinfo/needlestack).
MATERIAL AND METHODS

Needlestack overview
Needlestack estimates for each candidate alteration, i.e. each pair of position and base change (the three non-reference nucleotides and each observed insertions and deletions) the systematic sequencing error rate across a series of samples, typically more than twenty to ensure a reasonable estimation of this metric. Then, for each sample, it computes the p-value for the observed reads under the null hypothesis of this estimated model of errors, and transforms this p-value into a Phred-scale Q-value reported as a variant quality score (QVAL) for the candidate mutation. As such it measures the evidence that the observed mutation is not explained by the error model, and should therefore be considered a mutation.
Needlestack takes as input a series of BAM files, and is based on three main piped processes, the generation of the mpileup file containing read counts at the target positions using samtools (13) , the reformatting of this file into readable tabulated file and finally the estimation of the error model using our R regression script (see below) coupled with the computations of Q-values (Supplementary Figure 1) . Needlestack is highly parallelizable as input positions are analyzed independently. As an output, needlestack provides a multi-sample VCF file containing all candidate variants that obtain a QVAL higher than the input threshold in at least one sample, general information about the variant in the INFO field (e.g. error rate estimation, maximum observed QVAL) and individual information in the GENOTYPE field (e.g. QVAL of the sample, coverage of the sample at the position).
The Needlestack algorithm
Let i=1...N be the index of the sample taken from an aligned sequenced panel of size N, j the genomic position considered and k the potential alteration, with ∈ (A,T,C,G,ins,del), ins and del covering respectively every insertion and deletion observed in the data at position j. Let DP ij denote the total number of sequenced reads at position j for the sample i, AO ijk the reads count supporting alteration k and jk the corresponding error rate. We model the sequencing error distribution using a negative binomial (NB) regression (without intercept):
AO ijk~N B9 ijk ,σ jk < with kj the over-dispersion parameter and ijk =e jk * DP ijk corresponding to the expected number of reads supporting alteration k across samples with a coverage ijk . A robust negative binomial regression method (14) is employed to ensure that the outliers from this error model, such as true mutations, are not biasing the regression parameters estimates. This model is based on a robust weighted maximum likelihood estimator (MLE) for the over-dispersion parameter jk . We modified the original implementation of this regression to fit the need of our model here with: (i) a linear link function, (ii) a zero intercept, as a null coverage will exhibit a null read count, and (iii) an approximation of the bounding functions to allow the MLE to run efficiently for high coverage data (see Supplementary Methods).
For each position j and alternative k, we perform this robust negative binomial regression to estimate parameters jk and kj . We then consider a sample i as carrying a true mutation k at the position j when being an outlier from the corresponding error model. We calculate for each sample a p-value for being an outlier using the estimated parameters that we further transform into q-values using the Benjamini and Hochberg procedure (15) to account for multiple testing and control the false discovery rate.
Importantly, because true mutations are identified as the outliers from the error model fitted using a robust regression, this approach is more suited to detect low-abundance mutations. Common mutations (for example germline SNPs with common allele frequencies) will be observed in the error model and therefore not detected as outliers by needlestack. In practice we found that mutations with a minor allele frequency below 10% can be accurately detected (see below). Additionally, while allowing over-dispersion, our model assumes that the error rate jk is homogeneous across samples for a given alteration. This means that it should be applied to a homogeneous series of samples (that is prepared using comparable laboratory techniques and sequencing machines etc.). Importantly other types of errors that have less tendency to reoccur uniformly across samples are identified by needlestack as outliers.
Sequencing data for performance evaluation
125 cell-free DNA (cfDNA) samples from healthy donors were used to study the distribution of error rates estimated by needlestack and to estimate its accuracy to detect low VAF using in-silico mutations. We also sequenced 46 cfDNA samples from 18 small-cell lung cancer (SCLC) patients and 28 squamous-cell carcinoma (SCC) patients, two cancer types that harbour a high prevalence of TP53 mutations (respectively 99% (16) and 81% (17) ). In order to validate in the tumour the low VAF mutations identified by needlestack in the cfDNA, we also sequenced tumour samples for these patients. Each of the cfDNA samples was sequenced for the TP53 exonic regions (exons 2-11, which corresponds to 1,704 base pairs with a median coverage of around 10,000X) using the IonTorrent Proton technology, in two technical independent duplicates in order to account for potential errors during library preparation. Details about cfDNA sequencing steps and tumour sequencing method are provided in the Supplementary Material.
Additionally, we performed whole-exome sequencing (WES) from the blood of 62 samples from an independent cohort in order to estimate the performance of needlestack on germline mutations. As a gold standard, we used genotypes derived from Illumina SNP array (Illumina 5M beadarray) that were available for 33 of these 62 samples.
Comparison with other variant callers
We used BAMsurgeon software (18) to introduce single nucleotide variations (SNVs) at varied VAF in the 125 cfDNA samples in TP53 in order to benchmark and compare the method through in-silico simulations. BAMsurgeon presents the advantage of synthetic benchmarking methods that allow the simulation of mutations for which gold standards don't exist to evaluate the performance (here low VAF, that are in addition challenging to validate), while maintaining the real data background such as the true error profiles. We introduced 1000 SNVs at random positions in the gene in random samples, and we replicated this process in ten batches. As each sample has been sequenced twice, we introduced each in-silico mutation in the two technical duplicates of a sample. We took benefit from the variable coverage among samples and genomic positions to study the sensitivity of our method down to VAF=10 -4 . For each mutation m, the VAF was simulated using a log-uniform distribution:
VAF C =10 FG with ~uniform(0,4). Mutations were only introduced at positions where at least five mutated reads would be observed. This means that a mutation with a VAF=10 -4 would be introduced only in positions with a coverage of at least 50,000X. To compare needlestack with a similar variant caller, we ran ShearwaterML (4,10) on the same ten batches (see Supplementary Methods).
ShearwaterML is based on a beta-binomial regression and requires an a-priori threshold t for the error rate. ShearwaterML excludes each sample having a number of alternative bases higher than t*coverage, aiming at removing potential true mutations that act as outliers in the regression to robustly estimate the error rate. To compute the global performance of both methods, the ten simulation batches were merged, and only mutations detected in both technical duplicates were considered. In-silico simulations were repeated for 1-base pair insertions and deletions (indels) for needlestack. In this case, the total number of in-silico mutations was reduced to minimize the potential alignment artifacts created by the introduction of two indels close together. For that, using the same initial data, 100 insertions and 100 deletions were added again in ten simulations batches (total of twenty batches).
To estimate the ability of needlestack to detect rare germline variations, we used the 62 WES from blood samples. Needlestack variant calling was performed using our germline recommendations ( 
with # S,T being the number of estimated error rates in the class e observed for a base change b, and # S being the total number of estimated error rates in the class e.
In the case of the Ion Torrent sequencing, we observed a sufficiently high number of single nucleotide 
RESULTS
Sequencing error rates depend on the alteration type
Globally, 95% of the error rates across alterations were estimated as lower than 10 -2.5 in both sequencing technologies ( Figure 1A ). Nevertheless, the error rates varied importantly across the target sequences and alterations. For the amplicon-based Ion Torrent sequencing, transitions had 5-fold higher error rates than transversions ( Figure 1A ), on average, although not clearly influenced by the sequence context when considering the flanking 3′ and 5′ bases (Supplementary Figure S2) . For exome-capture sequencing, a bulk in the distribution of transversion-like errors is observed at an error rate in the order of 10 -2.5 ( Figure 1A ). When looking at the proportion of different nucleotide substitutions across multiple ranges of sequencing error rates ( Figure 1B ), we observed that in this range (10 -2 -10 -3 ) the majority of substitutions correspond to G>T transversions, previously reported and suggested to be related to DNA sonication (21) .
As previously reported, we observed a large number of indels (9, 389) in the Ion Torrent sequencing data (22) . We found that the error rate is dependent of their length: long indel (with a size greater than 3bp) error rates are around 100-fold lower than 1bp indel error rate (Supplementary Figure S3A) . As previously reported (22) , the error rate also increases with the length of homopolymer region, reaching 1% for repetitions of four nucleotides (Supplementary Figure S3B) .
Variant detection limit depends on the error rate
Importantly, errors identified in the previous section are classified as such by needlestack, and not as potential variants, even when the error rate is high, as opposed to traditional variant callers which consider samples individually and that rely mostly on the VAF (21) . Figure 2A illustrates a position at which needlestack identifies a high error rate ( jk = 3.8) without reporting any variant, even though alternate reads are observed in individuals VAF's up to ~ 9%. Figure 2B illustrates a position with a very different estimated error rate ( jk = 10
F[ ) where a putative very rare variant is identified. It is also noteworthy that the variant identified in Figure 2B has a VAF ten times lower (10 F\ ) than the error rate estimated in Figure 2A , indicating that the sensitivity to detect a variant is considerably improved at the site with the lower error rate, highlighting the need to quantify the error rate distributions for each candidate mutation independently.
Technical replicates reduce low VAF false calls
We noted that the majority of variants detected by needlestack in the cfDNA of healthy patients harbour a particularly low VAF, typically under 0.5% ( Figure 3A , black solid line). Importantly, the majority of these variants are not present in a second library preparation (a technical duplicate) of the same sample ( Figure 3A , blue lines). Such variants illustrate an additional type of errors found in NGS data that do not consistently re-occur in the samples and that are not validated when sequencing a technical replicate of the sample, for example those introduced by polymerase chain reaction (PCR) amplification errors. These non-systematic artefacts are not expected to be captured by our error model and should be detected by needlestack as outliers (see Figure 2C for such an example).
Importantly, we showed that this high number of calls not validated in a technical replicate of the sample is not dependent on our method ( Figure 3A , blue lines). Subsequently, here, for the evaluation of needlestack's ability to detect efficiently low VAF mutations, we added the condition that variants are also detected in the technical duplicates to account for this type of error ( Figure 3A , blue line).
Performance evaluation using in-silico simulation of somatic mutations
From the 10,000 mutations introduced by BAMsurgeon, needlestack detected 5% of mutations with a VAF lower than 0.1%, 51.4% of mutations with a VAF between 0.1% and 1%, and 99.4% of mutation with a VAF higher than 1%. As expected, the sensitivity of needlestack is highly dependent on the sequencing error rate. Indeed, needlestack does not call a mutation if the sequencing error rate for that alteration is greater than or in the same range as the VAF of the candidate mutation ( Figure 4 ).
As an example, needlestack detected 0%, 6.5%, and 47.8% of SNVs with a VAF of 0.1% at positions where the sequencing error rate was higher than 0.1%, between 0.1% and 0.01%, and lower than 0.01%, respectively. When comparing needlestack and shearwaterML, we found that globally needlestack sensitivity was higher than that of ShearwaterML, and, for example, ShearwaterML detected 7.7% of all inserted mutations with a VAF at 10 -3 whereas needlestack detected 16.8% of these mutations. Given t the shearwaterML a-priori threshold on the sequencing error rate ( Figure 3B red line) and e the observed sequencing error rate, we showed that the false positive rate of shearwater is markedly increased when t>e, whereas needlestack's false positive rate is stable across the whole range of error rates ( Figure 3B ).
Detection of tumour-derived mutations from cell-free DNA
Next, we tested needlestack's ability to detect very low VAF mutations in a biologically relevant 
Application to germline variant calling
For rare germline variants from 33 whole exomes, needlestack has a sensitivity of 95.64% to detect non-reference genotypes when using bead array data as a gold standard, which is quite similar to the
GATK-HC Haplotype Caller results (95.48%). GATK-HC and needlestack variants concordant with
the bead array (19,515 of the 20,439 variants) had VAF distributed around 50% and 100%, as expected for germline variants ( Figure 5A ). Most of the few calls that were not validated in the array were also centred around 50% and found by both variant callers, implying that they certainly contain additional heterozygotes that the SNP array failed to detect. Finally, the majority of variants not identified with NGS had no sequencing reads supporting the alternative allele detected by the array (841/892 variants), suggesting that these variants are potentially false positive results from the SNP array ( Figure 5A ). Figure S6) .
DISCUSSION
The needlestack method is based on the notion that, as error rates strongly vary along the genome, their dynamic estimation from multiple samples, for each potential base change at a given DNA position, may assist in accurately identifying sequence variants. Here, we have demonstrated that, even within a single gene (TP53), and even if the sequencing error rate is generally low, it varies importantly across positions and base changes (Figure 1 ). Needlestack implements a robust negative binomial regression for this purpose, and the ability of the method to identify variants will be dependent upon the error rate at that particular site and for that base change. By identifying sequence variants as outliers relative to the error model, needlestack maximizes the sensitivity to detect variants in a dynamic manner relative to the error rate in that particular setting. As such, low allelic fraction variants are identified from sites with low errors rates, whereas in settings where error rates are high, needlestack maintains reasonable false discovery rates (Figures 3 and 4) .
We have benchmarked our method using both simulated and real data from different sequencing platforms. First, we have tested our method on low VAF mutations using BAMsurgeon to generate in-silico mutations and have compared our findings to variants identified by a similar rare variant orientated algorithm shearwaterML (9, 10) . We have shown that our method outperforms shearwaterML for VAF lower than 10 -2 and that the performance of shearwaterML highly depends on the difference between the error rate e and the error rate a-priori threshold t (see methods for details).
Contrary to shearwaterML, needlestack's false discovery rate is not dependent on the sequencing error rate. In addition, needlestack also considers indel mutations. For this type of variant, the sensitivity of needlestack is slightly reduced compared to SNVs (Supplementary Figure S5A-B) . This is potentially due to the increased complexity of the assembly step around indels compared to SNVs.
Moreover, needlestack detects a high number of indels replicated in the two technical duplicates that
were not in-silico introduced (around 8 by samples in average), whereas TP53 is not expected to harbour many indels in healthy patients. These mutations can be moderated using a filter on the strand bias, as previously reported (Supplementary Figure S5C-D) (26) .
The true specificity of needlestack cannot be achieved with BAMsurgeon simulations, due to a probably very low presence of true mutations in the cfDNA of healthy patients that is difficult to determine a priori (20) . We therefore have estimated the validation rate in the tumour of deleterious cfDNA mutations identified by needlestack in 35 lung patient cfDNA samples. All of these 12 mutations were validated in the tumour.
Finally, we have benchmarked needlestack on germline mutations using SNP array data to validate the mutations detected in WES of 33 individuals, and showed an excellent concordance when results are compared with both a SNP array as a gold standard set and calls from GATK
HaplotypeCaller (19) . This illustrates that needlestack, even if based on a totally different approach to detect variants, can reach similar performance to state-of-the-art germline variant callers.
The needlestack method nevertheless has several limitations. Even though needlestack is extremely sensitive, it is suited to detect rare mutations rather than common germline variants or highly re-occurring hotspot mutations. Adding an a-priori threshold for the error rate (extra_robust mode -see Supplementary Methods) can partially offset this limitation, but is only applicable to particular situations for the reasons explained above. More importantly, the inherent logic of the needlestack approach corrects for errors that have a tendency to reoccur, as such errors that are rarer are identified as outliers in the regression. Following this, needlestack does not correct for sample-specific artifacts such as (i) (sample specific) stochastic alignment errors and we recommend to use it in conjunction with an assembly based re-alignment method (27) ; (ii) polymerase errors introduced in PCR amplification step; (iii) complex errors leading to features like strand bias. Such errors remain a feature in NGS data ( Figures 2C and 3A) , thus additional error correction (28, 29) and/or validation techniques are needed. This can be achieved with hard filtering on the output statistics such as the VAF or the strand bias, but also with machine-learning-based approaches applied to multiple variant summary statistics when validated data are available to inform the model.
Here we have controlled for these errors by undertaking technical duplicate of each sample and conditioning on the requirement that the variant must be present in each preparation.
Our pipeline is implemented using nextflow (12) , to facilitate its scientific reproducibility but also efficient parallel computations. Needlestack is also provided with Docker (30) and singularity (31) containers to avoid installation of dependencies and produce perfectly reproducible results.
Needlestack is a user-friendly pipeline that can be run in one command line. In addition, needlestack implements a power calculation to estimate if the coverage is sufficient to call a mutation (see Supplementary Methods for details). Using this power analysis, it can predict the germline or somatic status of a mutation when applied to tumour-matched normal mode. This also allows needlestack to flag mutations with an "unpredictable" status (when the coverage is to low) to accurately control the false discovery rate. Source code is available on GitHub and is versioned using a stable git branching model. Importantly, this approach is relatively computationally efficient and parallelisable. This allows error models to be built even across large target stretches of DNA, enabling applications at the exome level, genome levels or to most forms of sequencing data. 
AVAILABILITY
needlestack is an open source software and is available in the GitHub repository (https://github.com/IARCbioinfo/needlestack). Black line corresponds to the global sensitivity for all the mutations independently of the sequencing error rate. Global sensitivity of shearwaterML for the same data is shown in grey. 
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Robust Negative Binomial regression
The original method (1) was established on falls data where the predictor variable took values from 0 to a couple of hundreds. Here we need to take into account cases where we sequenced deeply and therefore the predictor variable DP can be up to hundreds of thousands. The first model uses integrals of bounding functions for the maximum likelihood estimation (MLE) of jk to keep robustness, which can take a very long time for high coverage data. To save computing time, we approximate the calculation of integrals required for the MLE of jk . Instead of computing the sum of all values corresponding to the integral, we interpolate the points using the spline function in R, and compute the sum of a set of sampling points with a reasonable size (default is 100).
The initial estimation of jk for the MLE algorithm is based on a Poisson model, and because of a lack of robustness the following MLE of jk can take a lot of time. We thus define our initiation of jk as the mean of observed ijk after passing the Tukey's outlier filter, i.e an observed ijk is taken into account for the mean computation if and only if it verifies ijk ≤ ( + 1.5 * IQR, with Qi=i th quartile and IQR=Q ( − ; .
Implementation
Needlestack is implemented as one major process, which can be executed in parallel for multiple input chunks, each corresponding to a set of genomic positions. This process is defined as a chain of piped commands: firstly, it runs samtools mpileup utility to compute, for each of the input BAM files, the list of read nucleotides overlapping the input positions. Then, it translates the samtools output into an easier to process format through a custom C++ tool (mpileup2readcount). Finally, needlestack uses its own R script to run the variant calling independently at each position and for each observed alternative base change, and produces a resulting VCF file that will be merged with other created VCF if run in parallel mode. See Supplementary Figure 5 for details on the pipeline. Needlestack is written in the nextflow (2) domain-specific language, allowing high scalability and reproducibility, but also efficient parallel execution. Needlestack source code is freely available on Github (3), and a Docker container image is hosted on DockerHub (4). This docker image is based on conda and Bioconda (5), a sustainable and comprehensive collection of bioinformatics software that help to easily install workflow dependencies.
Tumour-Normal pairs method
We have implemented, in addition to our basic model, a method to classify any observed variant as somatic or germline when needlestack is launched in tumour-normal pairs mode (Supplementary Table S2 ). For this, for each variant detected only in either the normal or tumor sample, needlestack estimates the power to detect it in the other sample. Indeed, not observing a variant in the other sample could be due to the lack of power to detect it, in particular when the depth of coverage is not sufficient. Our power metric is based on the expected Q-value of the variant if truly present, which depends on the observed coverage of the sample at the site, the expected allelic fraction and the error model estimated by Needlestack. If this Q-value is below the user-chosen threshold, we report a lack of power. For a particular individual sequenced for a tumour-normal pair, needlestack classifies its variants as follows: if a variant is observed in the tumour sample, it is classified as "somatic" if not observed in the normal although the power was sufficient, and as "unknown" in a case of a lack of power in the normal sample. If a variant is observed in the normal sample, it will be labeled as "germline", and sub-labeled as "confirmed" if also found in the tumour, "unconfirmed" if not found in the tumour whereas power was satisfactory, and "unconfirmable" if there was not enough power in the tumour to detect it if present.
To obtain the expected Q-value of a variant, the first step is the computation of the minimum expected alternative read count (6) in the other sample (tumor or normal). The expected AO of a (germline)
variant in the normal sample is computed as follows:
with C99 the 99 th centile, NB=negative binomial distribution, μ=0.5 x coverage at the position, and σ=dispersion parameter (by default=0.1).
The expected AO of a variant in the tumor sample is computed as follows:
with C99 the 99 th centile, B=binomial distribution, n=coverage at the position, and p=minimum variant allelic fraction expected (by default=0.01).
Then, given this expected AO, we compute the expected p-value that corresponds to the probability to belong to the error model that needlestack has estimated. Finally, we transform this p-value into a Phred-scale Q-value to obtain the expected Q-value of the variant. 
Bioinformatics processing
Short reads from NGS sequencing were aligned to the hg19 human reference genome using the Torrent Suite software (v4.4.2) with default parameters. Somatic mutations were detected with needlestack using the version 1.0 and a QVAL threshold at 50. As recommended by Martincorena et al. (7), we used a threshold of 20 for the shearwaterML statistic.
Only cfDNA mutations detected in a high confidence base change were considered. A high confidence base change satisfied P<0.05 with P the probability that the number of duplicated mutations under the null hypothesis would be greater than or equal to the observed number of duplicated mutations, and is given by:
with Cp corresponding to the probability of observing p pairs when randomly picking k elements from a total of 2N paired elements calculated as:
with N the number of sequenced samples in duplicates (2N sequenced libraries in total), k the number of libraries with a mutation called by needlestack, pobs the number of duplicated called mutations, and pmax the total number of possible pairs when picking up k elements from a total of N pairs of elements.
The detailed source code for cfDNA mutation analysis including all quality filtering step description is available on GitHub at: https://github.com/IARCbioinfo/target-seq.
For the germline analysis, GATK-HC variant calling was performed using version 3.4 and the HaplotypeCaller algorithm, followed by the joint genotyping step (8) . Finally, Variant Quality Score
Recalibration following the GATK best practices was applied, using dbSNP 138, HapMap 3.3, 1000
Genomes phase 1 and OMNI 2. Needlestack germline calling was launched using our default germline parameters, i.e. QVAL>20, VAF>0.1 and the option --extra-robust. This option helps needlestack to correctly estimate the error rate by excluding common germline variants (defined when more than 10% of the samples with a VAF higher than 20%) that tend to bias this estimation towards high values. For each of these base changes independently, this process first eliminates these germline samples and then estimates the error rate on remaining samples. In this germline analysis, both positions and variants with respectively a median coverage and an individual coverage less than 50 were removed from the whole analysis. Coverages were computed with samtools mpileup, counting only reads with a mapping quality higher than 20 and a base quality higher than 13. We considered as variant frequency the maximum proportion of samples carrying the variant estimated by both methods and then filtered out germline variants with a frequency higher than 10% to consider only rare variations.
Computation of ShearwaterML statistic used in the BAMsurgeon in-silico simulations
We launched the shearwaterML algorithm on the simulation data sets to compare its global performance with needlestack. As recommended by Martincorena et al. (7), we used a threshold of 20
for the shearwaterML statistic. We used default thresholds except that we increased maxvaf to 1 to call all mutations, and set truncate to 0.005 to avoid true mutations present initially at low VAF to enter the background error model and potentially reduce the sensitivity, as recommended in Martincorena et al. (7) . ShearwaterML produced p-values instead of the shearwater Bayes factor, that we corrected for multiple testing using the Benjamini-Hochberg method which produces then Q-values that we finally transformed into Phred scale Q-values (QVAL).
Using needlestack to compute the error rate distribution
Needlestack can be forced to compute the error rate for the three possible single nucleotide changes at every query position (i.e. to output the results of the error model even when no variants are identified). This can be achieved by launching needlestack with parameters --all_SNVs, --min_ao 0 and --min_dp 1. This way, in our analysis, the 5112 error rates across the TP53 gene were computed.
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